| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 05/23/2023 | Landos Biopharma, Inc. | LABP | Grant | Stock Option (right to buy) | 18k | $0.33 | $5.9k | | 05/23/2023 |
| 06/09/2022 | Astria Therapeutics, Inc. | ATXS | Grant | Stock Option (right to buy) | 8.3k | $2.99 | $24.9k | | 06/09/2022 |
| 06/09/2022 | Astria Therapeutics, Inc. | ATXS | Grant | Stock Option (right to buy) | 8.3k | $0.00 | $0 | | 06/09/2022 |
| 06/07/2022 | Landos Biopharma, Inc. | LABP | Grant | Stock Option (right to buy) | 18k | $0.91 | $16.5k | | 06/07/2022 |
| 05/16/2022 | Landos Biopharma, Inc. | LABP | Grant | Stock Option (right to buy) | 18k | $0.64 | $11.6k | | 05/16/2022 |
| 08/27/2021 | Landos Biopharma, Inc. | LABP | Grant | Stock Option (right to buy) | 36k | $14.18 | $510.5k | | 08/27/2021 |
| 06/02/2021 | Astria Therapeutics, Inc. | ATXS | Grant | Stock Option (right to buy) | 85k | $2.04 | $173.4k | | 06/02/2021 |
| 02/01/2021 | Astria Therapeutics, Inc. | ATXS | Grant | Series X Convertible Preferred Stock | 1.6k | $3,009.53 | $4.9M | By Perceptive Xontogeny Venture Fund, LP | 02/01/2021 |
| 01/28/2021 | Astria Therapeutics, Inc. | ATXS | Grant | Stock Option (right to buy) | 15k | $2.43 | $36.4k | | 01/28/2021 |